M&A Deal Summary |
|
---|---|
Date | 2022-03-28 |
Target | Jazz Pharmaceuticals - Sunosi |
Sector | Life Science |
Buyer(s) | Axsome |
Sellers(s) | Jazz Pharmaceuticals |
Deal Type | Divestiture |
Deal Value | 53M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2012 |
Sector | Life Science |
Employees | 589 |
Revenue | 271M USD (2023) |
Axsome is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through the development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. Axsome was founded in 2012 and is based in New York City.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Divestiture) | 1 of 1 |
Country (Ireland) | 1 of 1 |
Year (2022) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
Category | Company |
---|---|
Founded | 2003 |
Sector | Life Science |
Employees | 2,800 |
Revenue | 3.8B USD (2023) |
Jazz Pharmaceuticals is a specialty biopharmaceutical company that identifies, develops, and commercializes products to address unmet medical needs in focused therapeutic areas. Jazz Pharmaceuticals was founded in 2003 and is based in Dublin, Ireland.
DEAL STATS | # |
---|---|
Overall | 2 of 2 |
Sector (Life Science) | 2 of 2 |
Type (Divestiture) | 2 of 2 |
Country (Ireland) | 1 of 1 |
Year (2022) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-02-03 |
GW
Cambridge, United Kingdom GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. |
Buy | $6.7B |